Patients of physicians with a high number of co-worker reports about unprofessional behavior are at a significantly increased risk of surgical and medical complications, according to a June 19, 2019 paper published in JAMA Surgery. The study authors recommend that healthcare organizations foster better communication and collaboration, as failing to do so could undermine their cultures of safety...
Patients of physicians with a high number of co-worker reports about unprofessional...
As the son of a dermatologist and his namesake, Patrick Bitter Jr., MD, might have...
The eyes have been called the windows to the soul and the doorway to the heart. But...
It’s common for healthcare facilities, including private practices, to contract out...
Silagen Topical Recovery Gel from NewMedical Technology helps reduce...
The InMode AccuTite radiofrequency-assisted lipolysis (RFAL) device features...
Resurface Glycolic Renewal Serum from Neostrata features a 12 percent...
Cynosure TempSure Surgical radiofrequency (RF) technology—a new addition to...
 Revance Therapeutics has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines. The submission includes results from the three SAKURA Phase 3...
|
 Baring Private Equity Asia (BPEA) has agreed to acquire Lumenis, a provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an enterprise value of over $1 billion.
Lumenis has a...
|
Revance Therapeutics has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines. The submission includes results from the three SAKURA Phase 3 trials in which DAXI demonstrated that half of the patients treated maintained none or only mild frown lines for at least 24 weeks (approximately six months) after a single treatment. Additionally, frown lines did not return to their pre-treatment severity for at least 26–28 weeks for half of the patients treated.
“Based on the SAKURA trial results, DAXI has the potential to provide patients with lasting, natural-looking frown line correction all year long with just two treatments. Following this submission, Revance enters a catalyst-rich calendar year of significant clinical trial readouts and meaningful company milestones, which we believe will culminate in the approval and launch of DAXI in the aesthetic marketplace,” said Mark Foley, President and Chief Executive Officer of Revance.
Under the current Prescription Drug User Fee Agreement (PDUFA), the FDA has agreed to file acceptable applications within 60 days of receipt...
Baring Private Equity Asia (BPEA) has agreed to acquire Lumenis, a provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an enterprise value of over $1 billion.
Lumenis has a presence in over 100 countries and close to 1,500 employees worldwide. The Asia Pacific region is its largest market, together with a strong presence in North America and EMEA.
“BPEA’s investment is a tremendous vote of confidence in Lumenis and in the achievements of our entire global organization,” said Tzipi Ozer-Armon, CEO of Lumenis. “In recent years, we have developed and introduced multiple groundbreaking technological solutions that have redefined our industry and opened entirely new market segments. I would like to thank the entire Lumenis team, I am truly proud of all we have accomplished and honored to lead a company on the cutting edge of healthcare innovation, committed to improving the lives of people across the world. We look forward to partnering with the team at BPEA to continue developing and delivering to the world better technology for better patient care.”
The transaction remains subject to the...
Hologic has entered into a definitive agreement to sell Cynosure to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. Under the terms of the agreement, approximately 825 employees will transfer with the Cynosure business. The transaction is expected to close around the end of calendar 2019, subject to regulatory approvals and other customary conditions.
“Divesting our medical aesthetics business will enable us to focus on what we do best—helping women and their families live healthier lives through early detection of disease,” said Steve MacMillan, president and CEO of Hologic.
Hologic also announced that it intends to enter into an accelerated share repurchase (ASR) program to buy back $205 million of the company’s common stock. The ASR will be completed pursuant to a new $205 million share repurchase authorization that has been approved by Hologic’s board of directors.
Think of your most valuable employees—the ones who know the ins and outs of your practice, keep your office running smoothly, and are respected and liked by patients and staff. Now suppose those star staffers suddenly quit. How would that affect your day-to-day practice and profits?
Owners of thriving aesthetic practices know that knowledgeable, motivated, long-term employees are key to their success. And it’s not just high turnover rates that can damage a practice. Unhappy, dissatisfied team members can also wreak havoc on your bottom line. “If staff members are not happy, it can... more »
Patients who suffer from rosacea may exhibit any number of uncomfortable symptoms, from flushing and dilated capillaries to papules, pustules and ocular irritation. Treatment options similarly vary, as do theories as to what the underlying causes of rosacea may be. While recent research highlights cardiovascular links and explores the potential role of facial microorganisms, experts agree that the best treatments for rosacea target the chronic inflammation of the skin and body, and require a holistic approach to patient care. Patients most commonly present with erythematotelangiectatic... more »
At age six, Julius Few, MD, already knew exactly what he wanted to be when he grew up: a doctor—specifically, a surgeon. His inspiration: Dr. Quincy, a forensic pathologist played by actor Jack Klugman in the 1970s television series Quincy M.E. Of course, Dr. Quincy’s fictitious patients were dead, but that fact escaped the young Julius Few.
“Quincy was a sleuth,” says Dr. Few. “When I saw him operating on people, I thought that was the coolest thing and I knew that was what I wanted to do.”
Today, Dr. Few is the director and founder of The Few Institute for... more »
